OPFOLDA 65 mg Hard Capsules

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

Doctor
5.0(36)

Andrei Popov

General medicinePain medicine7 years of experience

Dr. Andrei Popov is a family physician with specialized training in the management of chronic pain. He provides video consultations for adults in Spain and across Europe: whether you have been living with pain for months that no one has been able to properly explain, or you need to resolve a health issue without waiting weeks for an appointment.

His approach is clear: to listen, organize your case, and provide you with a practical roadmap based on evidence-based medicine and adapted to your medical history and personal needs.

Pain: how he can help

  • Chronic pain (more than 3 months
  • Migraine and recurrent or high-intensity headaches
  •  Neck, lower back, back and joint pain
  •  Post-traumatic pain after injuries or surgeries
  •  Pain of neurological origin: neuralgia, neuropathic pain, fibromyalgia

General medicine

  • Frequent respiratory infections (cold, flu, persistent cough)
  • Hypertension, diabetes and metabolic disorders
  • Review of laboratory tests and MRI/CT reports (explained in clear language)
  • Preventive medicine and health monitoring
  • Second opinions and treatment adjustments (when clinically appropriate)

What the consultation is like
 Each session lasts up to 30 minutes. We review symptoms, medical history, medications and any tests you provide, and you finish the consultation with a clear treatment plan, defined next steps, and criteria to understand when follow-up may be needed. If warning signs are detected, he will clearly advise whether you need in-person care or urgent medical attention.

Book a video appointment
€86
This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use OPFOLDA 65 mg HARD CAPSULES

Contents of the leaflet

  1. Introduction
  2. What is Opfolda and what is it used for
  3. What you need to know before you take Opfolda
  4. How to take Opfolda
  5. Possible side effects
  6. Storage of Opfolda
  7. Contents of the pack and other information

Introduction

Package Leaflet: Information for the Patient

Opfolda 65 mg Hard Capsules

miglustat

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet

  1. What is Opfolda and what is it used for
  2. What you need to know before you take Opfolda
  3. How to take Opfolda
  4. Possible side effects
  5. Storage of Opfolda
  6. Contents of the pack and other information

1. What is Opfolda and what is it used for

What is Opfolda

Opfolda is a medicine used for the treatment of late-onset Pompe disease in adults. This medicine contains the active substance “miglustat”.

What Opfolda is used for

Opfolda is always used with another medicine called “cipaglucosidase alfa”, a type of enzyme replacement therapy (ERT). Therefore, it is very important that you also read the package leaflet of cipaglucosidase alfa.

If you have any questions about these medicines, ask your doctor or pharmacist.

How Opfolda works

People with Pompe disease have low levels of an enzyme called acid alpha-glucosidase (GAA). This enzyme helps regulate the levels of glycogen (a type of carbohydrate) in the body.

In Pompe disease, large amounts of glycogen accumulate in the muscles throughout the body. This prevents the muscles from working properly, for example, the muscles that help you walk, those that facilitate breathing in the lungs, and the heart muscle.

Opfolda binds to cipaglucosidase alfa during treatment. This makes the form of cipaglucosidase alfa more stable, so it can be more easily absorbed by the muscle cells affected by Pompe disease. Once inside the cells, cipaglucosidase alfa acts like GAA, promoting the breakdown of glycogen and regulating its levels.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Opfolda

Do not take Opfolda

  • If you are allergic to miglustat or any of the other ingredients of this medicine (listed in section 6).
  • If you are allergic to alpha cypaglucosidase.

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before you start taking Opfolda.

Pay attention to serious side effects

Opfolda is used together with cipaglucosidase alfa, a type of enzyme replacement therapy (ERT), so you should also read the package leaflet of cipaglucosidase alfa. These medicines can cause side effects that you should report to your doctor immediately, such as allergic reactions. The signs of an allergic reaction are listed in section 4 “Allergic reactions”.

These reactions can be serious and occur during or after administration of the medicine.

Tell your doctor or nurse immediately if you experience or think you may be experiencing a perfusion-associated reaction or an allergic reaction. Before taking Opfolda, tell your doctor or nurse if you have ever had a reaction of this type with another ERT.

Children and adolescents

This medicine must not be given to patients under 18 years of age, as the effects of Opfolda with cipaglucosidase alfa in this age group are unknown.

Other medicines and Opfolda

Tell your doctor or nurse if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription and herbal medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, ask your doctor or pharmacist for advice before taking this medicine.

There are no data on the use of Opfolda in combination with cipaglucosidase alfa during pregnancy. Your doctor will explain the risks and benefits of taking these medicines.

  • Do not take Opfolda or receive cipaglucosidase alfa if you are pregnant. Tell your doctor immediately if you become pregnant, think you may be pregnant, or plan to become pregnant. There may be risks for the unborn baby.
  • Opfolda in combination with cipaglucosidase alfa must not be used in women who are breastfeeding. A decision must be made whether to discontinue breastfeeding or discontinue the treatment.

Contraception and fertility

Women of childbearing potential must use effective contraceptive methods during treatment and for 4 weeks after stopping administration of both medicines.

Driving and using machines

Opfolda has no or negligible influence on the ability to drive and use machines. You should also read the package leaflet of cipaglucosidase alfa, as the medicine may affect the ability to drive and use machines.

3. How to take Opfolda

Follow exactly the instructions for administration of this medicine given by your doctor. If you are unsure, ask your doctor or pharmacist again.

How much Opfolda to take

  • Opfolda capsules (miglustat) must be used with cipaglucosidase alfa. Also, read the package leaflet of cipaglucosidase alfa.
  • If you weigh 50 kg or more, the recommended dose is 4 capsules, each containing 65 mg of miglustat.
  • If you weigh between 40 kg and 50 kg, the recommended dose is 3 capsules.

How often to take Opfolda

  • You will receive Opfolda and cipaglucosidase alfa every 2 weeks. Both are administered on the same day.
  • Follow exactly the instructions for administration of both medicines given by your doctor, see Figure 1. This way, the treatment can work as well as possible.

Taking Opfolda with food

You must take Opfolda orally on an empty stomach.

  • You will have to fast for 2 hours before and 2 hours after taking this medicine.
  • During this 4-hour fasting period, you can drink water, skimmed cow's milk, and tea or coffee. Do not drink cream, whole or semi-skimmed cow's milk, plant-based milks, sugar, or sweeteners. You can drink skimmed cow's milk with tea or coffee.
  • 2 hours after taking Opfolda, you can eat and drink normally again.

Figure 1. Chronological development of doses

Timeline showing 4-hour infusion duration with start and end of fasting indicated and pill with clock

  • Miglustat 65 mg hard capsule should be taken approximately 1 hour and no more than 3 hours before the start of cipaglucosidase alfa infusion.

Switching from another enzyme replacement therapy (ERT)

If you are currently receiving another ERT:

  • Your doctor will tell you when to stop the other ERT before starting Opfolda.
  • Tell your doctor when you received the last dose.

If you take more Opfolda than you should

Tell your doctor or go to the hospital immediately if you accidentally take more capsules than prescribed. You may be at a higher risk of side effects with this medicine (see section 4). Your doctor will provide the necessary symptomatic treatment.

If you forget to take Opfolda

If you forget to take a dose of Opfolda, talk to your doctor or nurse. Contact your doctor or nurse immediately to reschedule the administration of miglustat in combination with cipaglucosidase alfa as soon as possible.

If you stop taking Opfolda

Talk to your doctor if you want to stop taking Opfolda. Your symptoms may worsen if you stop treatment.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Opfolda is used together with cipaglucosidase alfa, and either of these medicines can cause side effects.

The following side effects may occur:

Allergic reactions

Allergic reactions can cause symptoms such as rash on any part of the body, swelling of the eyes, prolonged difficulty breathing, cough, swelling of the lips, tongue, or throat, itching of the skin, and hives.

Tell your doctor or nurse immediately if you experience or think you may be experiencing an allergic reaction. Tell your doctor or nurse if you have ever had a reaction of this type.

Very common(may affect more than 1 in 10 people)

  • Headache

Common(may affect up to 1 in 10 people)

  • Difficulty breathing (dyspnea)
  • Sudden redness of the face, neck, or upper chest
  • Increased blood pressure
  • Stomach pain
  • Abdominal swelling
  • Flatulence or gas
  • Diarrhea, loose stools
  • Constipation
  • Vomiting
  • Fatigue
  • Nausea
  • Fever
  • Itchy hives (urticaria)
  • Itchy rash, itching (pruritus)
  • Chills
  • Muscle cramps, pain, or weakness
  • Tremors in one or more parts of the body
  • Increased sweating
  • Pain
  • Altered sense of taste

Uncommon(may affect up to 1 in 100 people)

  • Asthma
  • Allergic reaction
  • Upset stomach
  • Indigestion
  • Pain or irritation of the throat
  • Painful or abnormal contractions of the throat
  • Malaise, general feeling of lethargy
  • Nervousness
  • Swelling of the hands, feet, ankles, legs
  • Feeling of constant tiredness
  • Unusual paleness of the skin
  • Low blood pressure
  • Decrease in platelets or a type of white blood cell (detected in blood tests)
  • Joint pain
  • Pain in the area between the hip and the ribs
  • Muscle fatigue
  • Increased muscle stiffness
  • Somnolence
  • Pain in one or both sides of the head, stabbing pain, aura, pain in the eyes, sensitivity to light (migraine)
  • Spots on the skin
  • Balance disorder

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Opfolda

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP”. The expiry date refers to the last day of the month shown.

No special storage conditions are required.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What Opfolda contains

  • The active substance is miglustat. Each hard capsule contains 65 mg of miglustat.
  • The other ingredients are:

Contents of the capsules

Pregelatinized starch (maize)

Magnesium stearate (E470b)

Microcrystalline cellulose (E460i)

Sucralose (E955)

Colloidal silicon dioxide

Capsule shell

Gelatin

Titanium dioxide (E171)

Black iron oxide (E172)

Printing ink

Black iron oxide (E172)

Potassium hydroxide (E525)

Propylene glycol (E1520)

Strong ammonia solution (E527)

Lacquer (E904)

Appearance and packaging

Bottles of 4 and 24 capsules.

Not all pack sizes may be marketed.

Hard capsule, size 2, with grey opaque cap and white opaque body with "AT2221" printed in black on the body, containing white to off-white powder.

Marketing authorisation holder

Amicus Therapeutics Europe Limited

Block 1, Blanchardstown Corporate Park

Ballycoolin Road

Blanchardstown, Dublin

D15 AKK1

Ireland

Tel: +353 (0) 1 588 0836

Fax: +353 (0) 1 588 6851

Email: [email protected]

Manufacturer

Manufacturing Packaging Farmaca (MPF) B.V.

Neptunus 12, Heerenveen, 8448CN, Netherlands

You can request more information about this medicine from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

Amicus Therapeutics Europe Limited

Tél/Tel: (+32) 0800 89172

e-mail: [email protected]

Lietuva

Amicus Therapeutics Europe Limited

Tel: (+370) 8800 33167

El. paštas: [email protected]

Amicus Therapeutics Europe Limited

Τηλ: (+359) 00800 111 3214

: [email protected]

Luxembourg/Luxemburg

Amicus Therapeutics Europe Limited

Tél/Tel: (+352) 800 27003

e-mail: [email protected]

Ceská republika

Amicus Therapeutics Europe Limited

Tel.: (+420) 800 142 207

e-mail: [email protected]

Magyarország

Amicus Therapeutics Europe Limited

Tel.: (+36) 06 800 21202

e-mail: [email protected]

Danmark

Amicus Therapeutics Europe Limited

Tlf.: (+45) 80 253 262

e-mail: [email protected]

Malta

Amicus Therapeutics Europe Limited

Tel: (+356) 800 62674

e-mail: [email protected]

Deutschland

Amicus Therapeutics GmbH

Tel: (+49) 0800 000 2038

e-mail: [email protected]

Nederland

Amicus Therapeutics BV

Tel: (+31) 0800 022 8399

e-mail: [email protected]

Eesti

Amicus Therapeutics Europe Limited

Tel: (+372) 800 0111 911

e-post: [email protected]

Norge

Amicus Therapeutics Europe Limited

Tlf: (+47) 800 13837

e-post: [email protected]

Ελλάδα

Amicus Therapeutics Europe Limited

Τηλ: (+30) 00800 126 169

e-mail: [email protected]

Österreich

Amicus Therapeutics Europe Limited

Tel: (+43) 0800 909 639

e-mail: [email protected]

España

Amicus Therapeutics S.L.U.

Tel: (+34) 900 941 616

e-mail: [email protected]

Polska

Amicus Therapeutics Europe Limited

Tel.: (+48) 0080 012 15475

e-mail: [email protected]

France

Amicus Therapeutics SAS

Tél: (+33) 0 800 906 788

e-mail: [email protected]

Portugal

Amicus Therapeutics Europe Limited

Tel: (+351) 800 812 531

e-mail: [email protected]

Hrvatska

Amicus Therapeutics Europe Limited

Tel: (+358) 0800 222 452

e-pošta: [email protected]

Ireland

Amicus Therapeutics Europe Limited

Tel: (+353) 1800 936 230

e-mail: [email protected]

România

Amicus Therapeutics Europe Limited

Tel.: (+40) 0808 034 288

e-mail: [email protected]

Slovenija

Amicus Therapeutics Europe Limited

Tel.: (+386) 0800 81794

e-pošta: [email protected]

Ísland

Amicus Therapeutics Europe Limited

Sími: (+354) 800 7634

Netfang: [email protected]

Slovenská republika

Amicus Therapeutics Europe Limited

Tel: (+421) 0800 002 437

e-mail: [email protected]

Italia

Amicus Therapeutics S.r.l.

Tel: (+39) 800 795 572

e-mail: [email protected]

Suomi/Finland

Amicus Therapeutics Europe Limited

Puh/Tel: (+358) 0800 917 780

sähköposti/e-mail: [email protected]

Κύπρος

Amicus Therapeutics Europe Limited

Τηλ: (+357) 800 97595

e-mail: [email protected]

Sverige

Amicus Therapeutics Europe Limited

Tfn: (+46) 020 795 493

e-post: [email protected]

Latvija

Amicus Therapeutics Europe Limited

Tel: (+371) 800 05391

e-pasts: [email protected]

United Kingdom (Northern Ireland)

Amicus Therapeutics, UK Limited

Tel: (+44) 08 0823 46864

e-mail: [email protected]

Date of last revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.

Online doctors for OPFOLDA 65 mg HARD CAPSULES

Discuss questions about OPFOLDA 65 mg HARD CAPSULES, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

Doctor
5.0(36)

Andrei Popov

General medicinePain medicine7 years of experience

Dr. Andrei Popov is a family physician with specialized training in the management of chronic pain. He provides video consultations for adults in Spain and across Europe: whether you have been living with pain for months that no one has been able to properly explain, or you need to resolve a health issue without waiting weeks for an appointment.

His approach is clear: to listen, organize your case, and provide you with a practical roadmap based on evidence-based medicine and adapted to your medical history and personal needs.

Pain: how he can help

  • Chronic pain (more than 3 months
  • Migraine and recurrent or high-intensity headaches
  •  Neck, lower back, back and joint pain
  •  Post-traumatic pain after injuries or surgeries
  •  Pain of neurological origin: neuralgia, neuropathic pain, fibromyalgia

General medicine

  • Frequent respiratory infections (cold, flu, persistent cough)
  • Hypertension, diabetes and metabolic disorders
  • Review of laboratory tests and MRI/CT reports (explained in clear language)
  • Preventive medicine and health monitoring
  • Second opinions and treatment adjustments (when clinically appropriate)

What the consultation is like
 Each session lasts up to 30 minutes. We review symptoms, medical history, medications and any tests you provide, and you finish the consultation with a clear treatment plan, defined next steps, and criteria to understand when follow-up may be needed. If warning signs are detected, he will clearly advise whether you need in-person care or urgent medical attention.

Book a video appointment
€86
Doctor
5.0(19)

Nuno Tavares Lopes

Family medicineGeneral medicine18 years of experience

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Book a video appointment
€70
Doctor
0.0(0)

Hocine Lokchiri

General medicine21 years of experience

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Book a video appointment
€64
Doctor
0.0(0)

Muhammad Tayyab Altaf

General medicine3 years of experience

Dr. Muhammad Tayyab Altaf is a primary care physician with extensive international experience, offering online consultations for adults and children. His background includes clinical practice in Policlinico San Matteo Hospital Pavia in Italy, Mount Sinai Hospital in New York, United States and other healthcare settings, allowing him to manage a wide range of acute and chronic medical conditions with confidence and clarity.

His clinical expertise spans multi-system conditions, preventive care and long-term management of chronic diseases. Dr. Altaf combines hands-on experience with a strong research background in both medical and surgical fields, enabling him to provide accurate assessments and structured, evidence-based treatment plans. Patients value his ability to explain diagnoses clearly, outline next steps and support them in making informed healthcare decisions.

Online consultations with Dr. Altaf are suitable for many everyday and acute situations where a timely medical opinion can help determine the safest next steps. He evaluates and treats conditions affecting the cardiovascular, respiratory, gastrointestinal, neurological, haematological and endocrine systems. Common examples include:

  • hypertension and other blood pressure issues
  • ischaemic heart disease and angina
  • asthma, COPD and emphysema
  • pneumonia and lung fibrosis
  • gastroenteritis and digestive infections
  • liver conditions, including alcohol-related disease
  • epilepsy, seizures and post-stroke symptoms
  • dementia and cognitive decline
  • anaemia and other haematological changes
  • diabetes, thyroid disorders and pituitary disease
Many patients reach out when they experience new or worsening symptoms, fluctuations in blood pressure, non-severe chest discomfort, breathing symptoms, digestive issues, suspected infections, chronic fatigue or concerns that affect daily life. He also helps patients understand test results, adjust existing treatment plans and navigate long-term health strategies safely and effectively.

When clinically appropriate, Dr. Altaf can also provide health and fitness certificates, including documentation required for physical activity, sports participation or gym use, based on the patient’s health status and medical indications.

Some conditions are not suitable for online care. Severe chest pain, loss of consciousness, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack require immediate attention from local emergency services. Dr. Altaf prioritises patient safety and will guide you accordingly if your situation needs urgent in-person care.

In all consultations, Dr. Muhammad Tayyab Altaf focuses on clear communication, accurate diagnosis and patient-centred decision-making. His approach ensures that individuals and families feel informed, supported and confident in their next steps, no matter where they are.

Book a video appointment
€71

Get OPFOLDA 65 mg HARD CAPSULES Prescription Online

1

Fill in a 2-min form

Tell us your symptoms, history, and what medicine you're requesting.

2

Pick a doctor or let us assign

Choose a specialist or we'll match you with the next available doctor.

3

Doctor reviews your case

Usually within 30 minutes. They may ask follow-up questions via chat.

4

Collect from any pharmacy

Electronic prescription sent to your email — valid across Spain.

Frequently Asked Questions

Is a prescription required for OPFOLDA 65 mg HARD CAPSULES?

OPFOLDA 65 mg HARD CAPSULES requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.

What is the active substance in OPFOLDA 65 mg HARD CAPSULES?

The active ingredient in OPFOLDA 65 mg HARD CAPSULES is miglustat. This information helps identify medicines with the same composition but different brand names.

Who manufactures OPFOLDA 65 mg HARD CAPSULES?

OPFOLDA 65 mg HARD CAPSULES is manufactured by Amicus Therapeutics Europe Limited. Pharmacy brands and packaging may differ depending on the distributor.

Which doctors can assess the use of OPFOLDA 65 mg HARD CAPSULES online?

Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether OPFOLDA 65 mg HARD CAPSULES is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.

How to buy OPFOLDA 65 mg HARD CAPSULES in Spain?

Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.

You can buy OPFOLDA 65 mg HARD CAPSULES in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.

To obtain a prescription, you can use Oladoctor:

What are the alternatives to OPFOLDA 65 mg HARD CAPSULES?

Other medicines with the same active substance (miglustat) include MIGLUSTAT ACCORD 100 mg HARD CAPSULES, MIGLUSTAT DIPHARMA 100 mg HARD CAPSULES, MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media